Truist Securities maintains buy rating on Regeneron stock

Regeneron (REGN) faces mixed sentiment following disappointing Phase 3 itepekimab COPD trial results, contributing to a recent stock decline; Truist maintains a Buy rating with a $940 target, while RBC downgraded to Sector Perform with a $662 target and BMO Capital lowered their target to $600. While Eylea headwinds persist and near-term sideways trading is expected, Regeneron's licensing agreement with Hansoh for an obesity drug candidate and promising Phase 2 data combining semaglutide with muscle-preserving antibodies offer potential long-term growth opportunities.

Analysis

Regeneron Pharmaceuticals (REGN) has experienced a significant 16.7% stock price decline over the past week, positioning it near its 52-week low, primarily attributed to mixed Phase 3 results for its chronic obstructive pulmonary disease (COPD) candidate, itepekimab. This development has prompted divergent analyst perspectives: Truist Securities reiterated a Buy rating with a $940 price target, anticipating near-term sideways trading due to itepekimab's unclear future pathway and ongoing headwinds for its key drug Eylea, yet remains optimistic about long-term growth driven by a robust pipeline. In contrast, RBC Capital Markets downgraded REGN from Outperform to Sector Perform, reducing its price target from $943 to $662, while BMO Capital maintained an Outperform rating but lowered its target to $600, both citing the disappointing itepekimab trial outcomes. Despite these clinical setbacks and Eylea challenges, InvestingPro data indicates Regeneron maintains strong fundamentals, including a healthy current ratio of 4.93 and more cash than debt. Strategically, the company is actively pursuing pipeline expansion, highlighted by a licensing agreement with Hansoh Pharmaceuticals for the Phase 3 obesity drug candidate HS-20094, involving an $80 million upfront payment and potential milestones up to $1.93 billion, and positive interim Phase 2 COURAGE trial results for a semaglutide combination therapy. However, Truist analysts caution that some upcoming pipeline readouts may offer only incremental progress or face significant competition, underscoring a cautious near-term outlook despite potential long-term opportunities.

Key Decisions for Investors

• Investors should carefully evaluate Regeneron's current valuation near its 52-week low and its strong balance sheet against the considerable near-term risks posed by the mixed itepekimab data and persistent Eylea headwinds.
• It is crucial to monitor upcoming catalysts, including further updates on itepekimab's regulatory path, the clinical progress of the licensed obesity drug HS-20094, and Eylea's commercial performance, to better gauge future growth prospects.
• Considering the divergent analyst ratings and price target adjustments, with Truist maintaining a Buy while RBC and BMO express increased caution, a prudent approach might involve waiting for greater clarity on pipeline developments or adopting a phased investment strategy to manage potential volatility.